Evaluation on the efficacy and safety of Chinese herbal medication Xifeng Dingchan Pill in treating Parkinson's disease: Study protocol of a multicenter, open-label, randomized active-controlled trial

Journal of Chinese Integrative Medicine

Volumn 11, Issue 4, 2013, Pages 285-290

  Zhang, Jie ^a,b   Ma, Yun Zhi ^b   Shen, Xiao Ming ^b  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b HENAN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Chinese herbal; Clinical protocols; Drug toxicity; Drugs; Levodopa; Parkinson disease; Randomized controlled trial

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; HERBACEOUS AGENT; PIRIBEDIL; UNCLASSIFIED DRUG; XIFENG DINGCHAN PILL;

ARTICLE; CHINESE MEDICINE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HERBAL MEDICINE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; PARKINSON DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; UNIFIED PARKINSON DISEASE RATING SCALE; UNSPECIFIED SIDE EFFECT;

EID: 84880989961     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jintegrmed2013035     Document Type: Article

References (19)

1. Zhang ZX, Roman GC, Hong Z, Wu CB, Qu QM, Huang JB, Zhou B, Geng ZP, Wu JX, Wen HB, Zhao H, Zahner GE. Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet. 2005; 365(9459): 595-597.
2. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007; 68(5): 384-386.
3. Wang Y, Yin S, Liu WG, Bian Y, Wang BM, Ye M, Lin XJ, Zhang L. Investigation on economic burden of disease and its related influence factors in patients with Parkinson disease. Lin Chuang Shen Jing Bing Xue Za Zhi. 2011; 24(6): 427-430. Chinese with abstract in English.
4. Bai QL, Feng Z. Effect of nourishing liver-kidney and extinguishing wind on Parkinson's disease of liver-kidney deficiency symptom. Liaoning Zhong Yi Za Zhi. 2010; 37(5): 846-849. Chinese with abstract in English.
5. Ma YZ, Liu J, Wang BQ, Li SF, Fu AM, Fang J, Lu SL, Lü FZ, Shen XM, Jia K, Zuo QX, Zhuang ZJ, Zhang M, Zhou XQ, Liu SS. Study on the effects of Xifeng Dingchan Pill in improving the efficiency and alleviating the toxicity symptoms of Madopar in patients with Parkinson's disease. National Achievement of Science and Technology. (2004) [2012-12-14]. http://dbpub.cnki.net/grid2008/dbpub/detail. aspx?QueryID=2. Chinese.
6. Bai QL, Ma YZ. Effect of Xifeng Dingchan Pill on syndrome of liver and kidney deficiency of Parkinson's disease: a report of 30 cases. Zhong Yi Za Zhi. 2010; 51(2): 125-127, 131. Chinese with abstract in English.
7. Ma YZ, Li SF, Shen XM, Jia K. Research on efficiency of traditional Chinese and Western medicine in treating 30 patients with Parkinson disease. Xin Zhong Yi. 2005; 37(10): 55-56. Chinese.
8. Ma L. A study on effects of Xifeng Dingchan Pill in treating 40 patients with Parkinson's disease. Zhong Yi Yan Jiu. 2008; 21(3): 39-42. Chinese.
9. Chen CH, Ma YZ, Ma L, Wang JF. Study on the effects of Xifeng Dingchan Pill on the Madopar dosage on Parkinson's disease. Shanxi Zhong Yi. 2007; 23(1): 35-36. Chinese with abstract in English.
10. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999; 56(1): 33-39.
11. Movement Disorder and Parkinson's Disease Group of Chinese Society of Neurology. Guidelines for the treament of Parkinson's disease. Zhonghua Shen Jing Ke Za Zhi. 2009; 42(5): 352-355. Chinese.
12. China Association of Traditional Chinese Medicine for Senile Encephalopathy. Diagnosis and efficacy evaluation criteria for senile tremor disease of traditional Chinese medicine. Beijing Zhong Yi Xue Yuan Xue Bao. 1992; 15(4): 39-41. Chinese.
13. Zheng XY. Clinical guideline of new drugs for traditional Chinese medicine (Draft). Beijing: China Medical Science Press. 2002: 5. Chinese.
14. Sun ZQ. Medical statistics. 3rd ed. Beijing: People's Medical Publishing House. 2011: 541-543. Chinese.
15. Bian ZX, Li YP, Moher D, Dagenais S, Liu L, Wu TX, Miao JX, Guan JL, Song L. Improving the quality of randomized controlled trials in Chinese herbal medicine, part I: clinical trial design and methodology. J Chin Integr Med. 2006; 4(2): 120-129. English with abstract in Chinese.
16. Palacios N, Gao X, Schwarzschild M, Ascherio A. Declining quality of life in Parkinson disease before and after diagnosis. J Parkins Dis. 2012; 2(2): 153-160.
17. Gao HM, Hong JS. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. 2008; 29(8): 357-365.
18. Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F. Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interv Aging. 2010; 5: 229-238.
19. Olanow W, Schapira AH, Rascol O. Continuous dopaminereceptor stimulation in early Pakinson's disase. Trends Neurosci. 2000; 23(10 Suppl): S117-S126.